Latest News-Ascentage Pharma Mediaroom_Page

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., June 15, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-06-15 07:39 16015

Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL

SUZHOU, China, and ROCKVILLE, MD, June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-06-08 07:30 4448

Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs

SUZHOU, China, and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-06-08 07:21 11160

ASCO 2021 | Ascentage Pharma to Announce Updated Data of Lisaftoclax (APG-2575) Demonstrating an ORR of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-05-20 08:44 4330

ASCO 2021 | Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-05-20 08:17 4603

Ascentage Pharma (6855.HK) Becomes a Constituent of MSCI China Small Cap Index

SUZHOU, China and ROCKVILLE, Md., May 13, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-05-13 08:28 1743

Ascentage Pharma to Announce Results from Four Clinical Studies at 2021 ASCO Annual Meeting, with Data of Its Drug Candidates Including Lisaftoclax (APG-2575) to Be Released in Oral Presentations for the First Time

SUZHOU, China and ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-04-21 08:38 2304

Ascentage Pharma Releases Preclinical Data of Its Core Drug Candidates at AACR Annual Meeting 2021, with Results Signifying the Potential of Multiple Combination Therapies in Cancer

SUZHOU, China and ROCKVILLE, Md., April 13, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-04-13 08:28 1970

Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-04-02 19:39 4833

Ascentage Pharma Announces 2020 Annual Results and Reports Launch Readiness for Its Core Drug Candidate

SUZHOU, China and ROCKVILLE, Md., March 31, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-03-31 23:27 1939

Ascentage Pharma Announces 2020 Annual Results and Reports Launch Readiness for Its Core Drug Candidate

Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115

SUZHOU, China and ROCKVILLE, Md., March 26, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-03-26 08:38 1826

Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation

SUZHOU, China and ROCKVILLE, Md., March 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-03-24 19:07 1614

Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021

SUZHOU, China and ROCKVILLE, Md., March 11, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-03-11 08:35 2573

Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer

SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-02-02 17:24 1619

Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company

SUZHOU, China and ROCKVILLE, Md., Jan. 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-01-29 08:29 1777

Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-01-14 09:32 2223

Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-01-05 08:32 2207

Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment

SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-12-22 18:29 1670

Ascentage Pharma Announces Updates on the Clinical Development of APG-2575, including an ORR of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

SUZHOU, China and ROCKVILLE, MD, Dec. 10, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-10 09:03 1821

Ascentage Pharma Announces Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) at 2020 American Society of Hematology (ASH) Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, Dec. 8, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-08 08:16 2127